Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 103-109

  Rosen, Lee S ^a,b  

^a Cancer Therapy Development Program

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IRINOTECAN; MITOMYCIN C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANOREXIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; LYMPHOMA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LEUKEMIA; LUNG NEOPLASMS; LYMPHOMA; NEOPLASMS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS;

EID: 0031796343     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Mori K, Ohnishi T, Yokoyama K, et al: A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 39:327-332, 1997.
2. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995.
3. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-1-pipendino)-1-pipendino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994.
4. Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn J Cancer Chemother 17:115-120, 1990.
5. Clavel M, Extra JM, Abigerges D, et al: French phase I studies of CPT-11 using 3 different schedules of administration. Ann Oncol 3(suppl 5):50, 1992.
6. Gandia D, Armand JP, Chabot GG, et al: Phase I study of the new camptothecin analog CPT-11 administered every 3 wk (abstract). Proc Am Assoc Cancer Res 33: A1560, 1992.
7. Clavel M, Mathieu-Boue A, Dumortier A, et al: Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days (abstract) Proc Am Assoc Cancer Res 33:A1568, 1992.
8. Culine S, de Forni M, Extra JM, et al: Phase I study of the camptothecin analog CPT-11, using a weekly schedule (abstract). Proc Am Soc Clin Oncol 11:A263, 1992.
9. Merrouche Y, Extra J-M, Abigerges D, et al: High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 15:1080-1086, 1997.
10. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990.
11. Tsuda H, Takatsuki K, Ohno R, et al: A late phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma (abstract). Proc Am Soc Clin Oncol 11:316, 1992.
12. Ota K, Ohno R, Shirakawa S, et al: Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia: The CPT-11 Research Group for Hematological Malignancies. Jpn J Cancer Chemother 21:1047-1055, 1994.
13. Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11): CPT-11 Study Group on Hematological Malignancy. Br J Cancer 70:771-774, 1994.
14. Tobinai K, Hotta T, Saito H, et al: Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma: CPT-11/Lymphoma Study Group. Jpn J Clin Oncol 26:455-460, 1996.
15. Kawato Y, Furuta T, Aonuma M, et al: Antitumor activity of a camptothecin derivative CPT-11 against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991.
16. Clavel M, Mathieru-Boue A, Dumortier A, et al: Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days (abstract). Proc Am Assoc Cancer Res 33:262, 1992
17. Taguchi T, Yoshida Y, Izuo M, et al: An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer. Jpn J Cancer Chemother 21:83-90, 1994.
18. Taguchi T, Tominaga T, Ogawa M, et al: A late phase II study of CPT-11 (irinotecan) in advanced breast cancer: CPT-11 Study Group on Breast Cancer. Jpn J Cancer Chemother 21:1017-1024, 1994.
19. Bonneterre J, Pion JM, Adenis A, et al: A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients (abstract). Proc Am Soc Clin Oncol 12:94, 1993.
20. Sakata Y, Wakui A, Nakao K, et al: A late phase II study of irinotecan (CPT-11), in advanced pancreatic cancer (abstract). Proc Am Soc Clin Oncol 12:211, 1993.
21. Wagener DJ, Verdonk HE, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer: An EORTC early clinical trials group study Ann Oncol 6:129-132, 1995.
22. Shimada Y, Rothenberg M, Hilsenbeck SG, et al: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drug 5:202-206, 1994.
23. Kawato Y, Furuta T, Aonuma M, et alAntitumor activity of a camptothecin derivative, CPT-11 against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991.
24. Takeuchi S, Takamizawa H, Takeda Y, et al: Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy (abstract). Proc Am Soc Clin Oncol 10:189, 1991.
25. Takeuchi S, Takamizawa H, Takeda Y, et al: An early phase II study of CPT-11 in gynecologic cancers: Research Group of CPT-11 in Gynecologic Cancers. Jpn J Cancer Chemother 18:579-584, 1991.
26. Takeuchi S, Dobashi K, Fujimoto S, et al: A later phase II study of CPT-11 on uterine cervical cancer and ovarian cancer: Research Group of CPT-11 in Gynecologic Cancers. Jpn J Cancer Chemother 18:1681-1689, 1991.
27. Sugiyama T, Nishida T, Ookura N, et al: Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer (abstract)? Proc Am Soc Clin Oncol 16:378a, 1997.
28. Sugiyama T, Nishida T, Kataoka A, et al: Combination of irinotecan hydrochloride (CPT-11 ) and cisplatin as a new regimen for patients with advanced ovarian cancer. Acta Obstet Gynecol Jpn 48:827-834, 1996.
29. Sugiyama T, Nishida T, Ushijima K, et al: Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer (abstract). Proc Am Soc Clin Oncol 15:291, 1996.
30. Shimizu Y, Umezawa S, Hasumi K: Combination of CPT-11 (CPT) with mitomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant (abstract). Proc Am Soc Clin Oncol 15:282, 1996.
31. Kajino T, Higuchi M, Hata K, et al: Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma. Jpn J Cancer Chemother 23:115-117, 1996.
32. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small-cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10:241, 1991.
33. Negoro S, Fukuoka M, Niitani H, et al: A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer: CPT-11 Cooperative Study Group. Jpn J Cancer Chemother 18:1013-1019, 1991.
34. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
35. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer J Natl Cancer Inst 83:1164-1168, 1991.
36. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
37. Le Chevalier T, Ibrahim N, Chomy P, et al.: A phase II study of irinotecan (CPT-11) in patients (pts) with small-cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol 16:450a, 1997.
38. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of innotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer (abstract). Proc Am Soc Clin Oncol 12:A331, 1993.
39. Fujiwara Y, Yamakido M, Fukuoka M, et al: Phase II study of innotecan (CPT-11) and cisplatin (CDDP) in patients with small-cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 13:335, 1994.